Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06620055
Recruiting Observational

Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas Gliomas

NCT06620055 · tracked via the Priya Life Science Italy tracker
Sponsor
Centro di Riferimento Oncologico - Aviano
Phase
Observational
Started
2023-11-16
Last updated
2024-10-01

Condition(s) studied

Glioma

Study summary

Artificial intelligence (AI) undoubtedly represents the main tool currently available in the definition of complex algorithms and its use in the medical field is becoming increasingly strategic.As reported in the literature, it is increasingly difficult to find new therapeutic strategies for neoplasms, especially neurological ones. Molecular characterisation is therefore increasingly essential, as is the use of new predictive methods.

With this in mind, the aim of this study is to assess, by means of AI algorithms applied to genomic data, in what percentage molecular alterations are susceptible to potential drug therapies, compared to the literature data that does not consider AI algorithms for this purpose.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients with a histopathological diagnosis of glioma for whom it is possible to have cryopreserved or fixed in formalin and embedded in paraffin biological material. Specimens may result from incisional biopsy and/or surgical resection and/or blood. Whole blood is taken for germinal analysis; 2. Age \>=18 years; 3. Patients must understand and provide written informed consent; 4. Life expectancy \>3 months; 5. Presence of biological material from resection and blood considered sufficient by quality and quantity to proceed to molecular characterisation in the opinion of the Investigator Principal Investigator; 6. Presence of available and accessible clinical and histopathological data. Exclusion Criteria: 1. Refusal of informed consent; 2. Uncooperative patients; 3. Presence of other neoplastic diseases in the last 5 years; 4. Pregnant and/or breastfeeding women

Primary outcome measure(s)

  • proportion of patients, out of total patients number, with molecular characteristics susceptible to potential drug therapies ('druggable') identified using an AI model — 24 months
    proportion of patients, out of total patients number, with molecular characteristics susceptible to potential drug therapies ('druggable') identified using an AI model

Trial sites (3)

FacilityCityRegionStatus
Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS Aviano Pordenone Recruiting
IOV Padova Italy Recruiting
Azienda Sanitaria Universitaria Friuli Centrale (ASUFC Udine Italy Recruiting

More Centro di Riferimento Oncologico - Aviano trials in Italy

Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer Recruiting
Precision Retrospective Integrative Study for Metastatic Lymph Nodes in Breast Cancer Recruiting
Prostate Cancer REsearch Using Cross-validation of Innovative Sampling, Integrating LC-MS/MS for Optimized Therapeutic Drug moNitoring Recruiting
Reference Intervals With Indirect Methods in Italy Recruiting
Identification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO) Recruiting

Other trials for the same condition

Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Recruiting
Connectome-guided Onco-functional Resection With Tractography-Extended Neuronavigation in Brain Tumor Surgery Recruiting
AI-driven Processing and Analysis of Glioma Imaging Data Recruiting
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06620055 on ClinicalTrials.gov ↗ ← All trials in Italy